Skip to content

Merck & Co. MRK Treasury Stock

Treasury Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$43.52B-0.2%
Pfizer logo
PfizerPFE
$115.19B+0.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$75.86B+0.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$19.41B+19.7%
United Therapeutics logo
United TherapeuticsUTHR
$5.44B+56.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total equity$45.9B-5.1%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$323.72B+53.4%
Enterprise value$367.42B+53.2%
P/E36.2×+23.4×
P/S4.9×+1.6×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s treasury stock?
Merck & Co. (MRK) reported treasury stock of $63.75B in Q1 2026.
How has Merck & Co.'s treasury stock changed year-over-year?
Merck & Co.'s treasury stock increased by 7.3% year-over-year, from $59.4B to $63.75B.
What is the long-term trend for Merck & Co.'s treasury stock?
Over 5 years (2020 to 2025), Merck & Co.'s treasury stock has grown at a 2.1% compound annual growth rate (CAGR), from $56.79B to $63B.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.